Pieris Pharmaceuticals, Inc. (PIRS) Financials
PIRS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 59.4 million | 28.9 million |
2023-06-30 | 87.5 million | 47.0 million |
2023-03-31 | 82.3 million | 66.8 million |
2022-12-31 | 95.5 million | 67.6 million |
PIRS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -9.8 million | 966000 |
2023-06-30 | -13.5 million | 1.0 million |
2023-03-31 | -11.0 million | 884000 |
2022-12-31 | -13.9 million | 949000 |
PIRS Net Income
No data available :(
PIRS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 44.8 million | - | 12.3 million |
2023-06-30 | 54.9 million | - | 12.8 million |
2023-03-31 | 48.4 million | - | 12.2 million |
2022-12-31 | 59.2 million | - | 13.1 million |
PIRS Shares Outstanding
PIRS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 69000 | 9.6 million | 6.8 million | - |
2023-06-30 | 67000 | 14.3 million | 3.7 million | - |
2023-03-31 | 48000 | 13.4 million | 4.0 million | - |
2022-12-31 | 1.0 million | 13.4 million | 4.0 million | - |
PIRS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 19.5 million | 739000 |
2023-06-30 | 20.1 million | 725000 |
2023-03-31 | 1.9 million | 571000 |
2022-12-31 | 5.8 million | 585000 |
PIRS
Price: $11.68
52 week price:
Earnings Per Share: -0.34 USD
P/E Ratio: -0.54
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 522800
Ebitda: -5.1 millionMarket Capitalization: 17.5 million